Literature DB >> 22477069

Combining cheminformatics methods and pathway analysis to identify molecules with whole-cell activity against Mycobacterium tuberculosis.

Malabika Sarker1, Carolyn Talcott, Peter Madrid, Sidharth Chopra, Barry A Bunin, Gyanu Lamichhane, Joel S Freundlich, Sean Ekins.   

Abstract

PURPOSE: New strategies for developing inhibitors of Mycobacterium tuberculosis (Mtb) are required in order to identify the next generation of tuberculosis (TB) drugs. Our approach leverages the integration of intensive data mining and curation and computational approaches, including cheminformatics combined with bioinformatics, to suggest biological targets and their small molecule modulators.
METHODS: We now describe an approach that uses the TBCyc pathway and genome database, the Collaborative Drug Discovery database of molecules with activity against Mtb and their associated targets, a 3D pharmacophore approach and Bayesian models of TB activity in order to select pathways and metabolites and ultimately prioritize molecules that may be acting as substrate mimics and exhibit activity against TB.
RESULTS: In this study we combined the TB cheminformatics and pathways databases that enabled us to computationally search >80,000 vendor available molecules and ultimately test 23 compounds in vitro that resulted in two compounds (N-(2-furylmethyl)-N'-[(5-nitro-3-thienyl)carbonyl]thiourea and N-[(5-nitro-3-thienyl)carbonyl]-N'-(2-thienylmethyl)thiourea) proposed as mimics of D-fructose 1,6 bisphosphate, (MIC of 20 and 40 μg/ml, respectively).
CONCLUSION: This is a simple yet novel approach that has the potential to identify inhibitors of bacterial growth as illustrated by compounds identified in this study that have activity against Mtb.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22477069      PMCID: PMC3601406          DOI: 10.1007/s11095-012-0741-5

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  43 in total

1.  Pathway databases: a case study in computational symbolic theories.

Authors:  P D Karp
Journal:  Science       Date:  2001-09-14       Impact factor: 47.728

2.  Pathway logic modeling of protein functional domains in signal transduction.

Authors:  C Talcott; S Eker; M Knapp; P Lincoln; K Laderoute
Journal:  Pac Symp Biocomput       Date:  2004

3.  An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence.

Authors:  L G Wayne; L G Hayes
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

4.  Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium.

Authors:  L Collins; S G Franzblau
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

5.  Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis.

Authors:  L R Camacho; D Ensergueix; E Perez; B Gicquel; C Guilhot
Journal:  Mol Microbiol       Date:  1999-10       Impact factor: 3.501

6.  Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B.

Authors:  Thompson N Doman; Susan L McGovern; Bryan J Witherbee; Thomas P Kasten; Ravi Kurumbail; William C Stallings; Daniel T Connolly; Brian K Shoichet
Journal:  J Med Chem       Date:  2002-05-23       Impact factor: 7.446

7.  Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis.

Authors:  Juan-Carlos Palomino; Anandi Martin; Mirtha Camacho; Humberto Guerra; Jean Swings; Françoise Portaels
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

8.  Genetic requirements for mycobacterial survival during infection.

Authors:  Christopher M Sassetti; Eric J Rubin
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-20       Impact factor: 11.205

9.  Characterization of a Mycobacterium tuberculosis H37Rv transposon library reveals insertions in 351 ORFs and mutants with altered virulence.

Authors:  Ruth A McAdam; Selwyn Quan; Debbie A Smith; Stoyan Bardarov; Joanna C Betts; Fiona C Cook; Elizabeth U Hooker; Alan P Lewis; Peter Woollard; Martin J Everett; Pauline T Lukey; Gregory J Bancroft; William R Jacobs; Ken Duncan
Journal:  Microbiology       Date:  2002-10       Impact factor: 2.777

10.  Genes required for mycobacterial growth defined by high density mutagenesis.

Authors:  Christopher M Sassetti; Dana H Boyd; Eric J Rubin
Journal:  Mol Microbiol       Date:  2003-04       Impact factor: 3.501

View more
  20 in total

1.  Computational models for neglected diseases: gaps and opportunities.

Authors:  Elizabeth L Ponder; Joel S Freundlich; Malabika Sarker; Sean Ekins
Journal:  Pharm Res       Date:  2013-08-30       Impact factor: 4.200

2.  Bayesian models for screening and TB Mobile for target inference with Mycobacterium tuberculosis.

Authors:  Sean Ekins; Allen C Casey; David Roberts; Tanya Parish; Barry A Bunin
Journal:  Tuberculosis (Edinb)       Date:  2013-12-19       Impact factor: 3.131

Review 3.  Collaborative drug discovery for More Medicines for Tuberculosis (MM4TB).

Authors:  Sean Ekins; Anna Coulon Spektor; Alex M Clark; Krishna Dole; Barry A Bunin
Journal:  Drug Discov Today       Date:  2016-11-22       Impact factor: 7.851

4.  Comparing and Validating Machine Learning Models for Mycobacterium tuberculosis Drug Discovery.

Authors:  Thomas Lane; Daniel P Russo; Kimberley M Zorn; Alex M Clark; Alexandru Korotcov; Valery Tkachenko; Robert C Reynolds; Alexander L Perryman; Joel S Freundlich; Sean Ekins
Journal:  Mol Pharm       Date:  2018-04-26       Impact factor: 4.939

5.  Bayesian models leveraging bioactivity and cytotoxicity information for drug discovery.

Authors:  Sean Ekins; Robert C Reynolds; Hiyun Kim; Mi-Sun Koo; Marilyn Ekonomidis; Meliza Talaue; Steve D Paget; Lisa K Woolhiser; Anne J Lenaerts; Barry A Bunin; Nancy Connell; Joel S Freundlich
Journal:  Chem Biol       Date:  2013-03-21

6.  Evolution of a thienopyrimidine antitubercular relying on medicinal chemistry and metabolomics insights.

Authors:  Shao-Gang Li; Catherine Vilchèze; Sumit Chakraborty; Xin Wang; Hiyun Kim; Monica Anisetti; Sean Ekins; Kyu Y Rhee; William R Jacobs; Joel S Freundlich
Journal:  Tetrahedron Lett       Date:  2015-06-03       Impact factor: 2.415

7.  Bigger data, collaborative tools and the future of predictive drug discovery.

Authors:  Sean Ekins; Alex M Clark; S Joshua Swamidass; Nadia Litterman; Antony J Williams
Journal:  J Comput Aided Mol Des       Date:  2014-06-19       Impact factor: 3.686

8.  Fusing dual-event data sets for Mycobacterium tuberculosis machine learning models and their evaluation.

Authors:  Sean Ekins; Joel S Freundlich; Robert C Reynolds
Journal:  J Chem Inf Model       Date:  2013-10-30       Impact factor: 4.956

9.  Combining computational methods for hit to lead optimization in Mycobacterium tuberculosis drug discovery.

Authors:  Sean Ekins; Joel S Freundlich; Judith V Hobrath; E Lucile White; Robert C Reynolds
Journal:  Pharm Res       Date:  2013-10-17       Impact factor: 4.200

10.  Enhancing hit identification in Mycobacterium tuberculosis drug discovery using validated dual-event Bayesian models.

Authors:  Sean Ekins; Robert C Reynolds; Scott G Franzblau; Baojie Wan; Joel S Freundlich; Barry A Bunin
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.